The nation’s public health insurance assessment organ has decided to provide conditional reimbursement for Xospata (ingredient: gilteritinib) in treating leukemia patients.The Health Insurance Review and Assessment Service (HIRA) reviewed whether it is appropriate to cover health insurance for Xospa
Takeda is strengthening its position in the anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) first-line treatment market with Alunbrig, armed with new data showing the drug’s superiority compared to other treatments.“If I had to choose just one, I would choose Alunbrig (I
Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukemia (AML), has taken a step closer to winning health insurance benefits.On Friday, the Health Insurance Review and Assessment Service (HIRA) released the result of the drugs benefit appraisal committee’s meetin
Samyang Biopharmaceuticals' U.S. subsidiary, Samyang Biopharm USA, is pushing to develop its cancer immunotherapy drug candidate, SYB-010, through global open innovation.Samyang Biopharm USA recently signed an agreement with the Spanish National Research Council, the largest public research institut
HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13.The clinical results showed a 40 percent overall response rate (ORR), 9
Hanall Biopharma said its Chinese partner, Harbour BioMed, has received approval from China's National Medical Products Administration (NMPA) to conduct a phase 2 clinical trial of HL161 for chronic inflammatory demyelinating polyneuropathy.Harbour BioMed signed an agreement with Hanall Biopharma in
Voronoi said that it has licensed out its autoimmune disease treatment program to Brickell Biotech.Under the accord, Voronoi will receive a down payment of $5 million and can receive up to $323.5 million depending on the development progress of the treatment candidate.The candidate inhibits the diff
Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, its acromegaly treatment, from this month.According to the current standard, the health authorities reimburse Somarvert to patients over 18 with acromegaly who have received surgery and radiation th
Domestic companies are jumping into the fray to develop therapies for stroke, like their multinational counterparts who have struggled to see significant results in their clinical trials.Actilyse (ingredient: alteplase), a tissue plasminogen activator (tPA) developed by Boehringer Ingelheim, is the
GSK and the German biopharmaceutical company CureVac said their second-generation mRNA Covid-19 vaccine demonstrated an improved immune response than the first generation, marking higher neutralizing antibody capacity against the variant strains.The preclinical study assessed the Covid-19 immune res
Korean pharmaceutical companies are actively conducting R&D to secure a share in the 21 trillion won ($18.1 billion) global gastric acid blocker market.In foreign markets, they are particularly focusing on commercializing potassium-competitive acid blockers (P-CABs), the next-generation treatment fo
Jazz Pharmaceuticals, SK Biopharmaceuticals’ U.S. partner, said that it has received sales approval for Sunosi (Ingredient: solriamfetol), a new sleep disorder drug, from the Canadian health authorities.With the approval, hospitals can prescribe the drug to treat adult patients suffering from excess
The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year amounted to about 1.91 trillion won ($1.6 billion), accounting for 9.3 percent of the total drug reimbursement payouts of 20.3 trillion won.According to the NHIS, medical expenses for healt
KangStem Biotech said that it has signed a deal with Seoul National University’s R&DB Foundation to receive the university’s skin organoid manufacturing technology.The technology uses a three-dimensional (3D) air-liquid interface (ALI) skin organoid preparation from human pluripotent stem cells for
GNT Pharma said Tuesday that it has received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial study of Nelonemdaz, a stroke treatment candidate."This is the first time that the government has approved phase 3 clinical trial for a locally developed stroke drug," the com
AstraZeneca plans to provide a new treatment option for chronic kidney disease patients after recently expanding the indication for Forxiga, initially developed as type-2 diabetes treatment, from regulators, the company said Monday.Some members of the Korean Society of Nephrology (KSN) also supporte
Medpacto said that the U.S. Food and Drug Administration has granted an orphan drug designation (ODD) to the combination therapy of Vactosertib and PD-L1 inhibitors for treating osteosarcoma.Vactosertib received the FDA designation for the second time this year alone. Medpacto received orphan drug d
Korean pharmaceuticals and biotech companies are speeding up the development of donepezil patches to treat Alzheimer’s disease. As patches are easier for patients to take than oral drugs, they draw attention to how they will affect the dementia market.Teaming up with Celltrion, Icure Pharmaceutical
Genexine said it has made a clinical strategic change of GX-19N, its Covid-19 vaccine candidate, to develop it as a booster shot that prevents breakthrough infections.“We have submitted the change of plans to the ethical committee (EC) of Fakultas Kedokteran Universitas Indonesia Hospital and the In
Novartis Korea presented a study on the treatment of Koreans with diffuse large B-cell lymphoma (DLBCL) patients and their financial burdens at an international conference last week.The company shared its findings identifying demographic characteristics, treatment patterns, and prognosis DLBCL patie